Bioxcel Therapeutics (BTAI) Price & Analysis

Compare

1,874 Followers

BTAI Stock Chart & Stats

$2.29

-$0.09(-19.80%)

At close: Jan 08 4:00 PM EST

$2.29

-$0.09(-19.80%)

Day’s Range― - ―

52-Week Range$1.17 - $13.28

Previous CloseN/A

Volume1.10M

Average Volume (3M)1.58M

Market Cap

$44.99M

Enterprise Value$104.56M

Total Cash (Recent Filing)$17.43M

Total Debt (Recent Filing)$108.69M

Price to Earnings (P/E)―

Beta2.38

Next Earnings

Nov 13, 2025

EPS Estimate

-1.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.45

Shares Outstanding19,646,801

10 Day Avg. Volume1,230,633

30 Day Avg. Volume1,584,008

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.16

Price to Sales (P/S)6.69

P/FCF Ratio-0.21

Enterprise Value/Market Cap2.32

Enterprise Value/Revenue120.46

Enterprise Value/Gross Profit-79.45

Enterprise Value/Ebitda-2.66

Forecast

1Y Price Target

$8.25

Price Target Upside260.26% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe SERENITY At-Home pivotal Phase 3 trial yielded positive exploratory efficacy data, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing.

Regulatory ProgressBTI now meets all Nasdaq Capital Market listing requirements and this matter is now closed.

Bears Say

Concerns About EfficacyMore questions than answers on efficacy releases.

Market Penetration ChallengesSignificant investment is needed to effectively penetrate the larger than anticipated addressable market of agitation episodes.

Bioxcel Therapeutics News

BioXcel announces results from correlation study from SERENITY At-Home trial

BioXcel Therapeutics (BTAI) announced positive results from the correlation study related to exploratory efficacy outcomes from the SERENITY...

8d ago

BTAI

BioXcel Announces Positive SERENITY At Home Study Results

An update from Bioxcel Therapeutics ( ($BTAI) ) is now available. On October 14, 2025, BioXcel Therapeutics announced...

8d ago

BTAI

Bioxcel Therapeutics: Buy Rating Affirmed Amid NASDAQ Compliance and Promising IGALMI™ Outlook

Bioxcel Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

30d ago

BTAI

BioXcel Therapeutics regains compliance with Nasdaq

BioXcel Therapeutics (BTAI) announced that it has received written notice from the Listing Qualifications Department of The Nasdaq...

1M ago

BTAI

Bioxcel Therapeutics Files Current Report on Form 8-K

Bioxcel Therapeutics ( ($BTAI) ) has provided an announcement. Bioxcel Therapeutics has made a disclosure in their Current...

1M ago

BTAI

BioXcel Therapeutics says has raised $37.3M since July 1 under ATM offering

On April 3, the company entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell shares...

1M ago

BTAI

BioXcel Therapeutics completes enrollment in clinical study

In a regulatory filing, the company said that on September 13, it completed enrollment in its open label...

1M ago

BTAI

Promising Phase 3 Trial Results and Growth Potential for Bioxcel Therapeutics’ BXCL501 Reinforce Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Bioxcel Therapeutics. The associated price target...

1M ago

BTAI

BioXcel Therapeutics price target raised to $4 from $2 at Mizuho

Mizuho raised the firm’s price target on BioXcel Therapeutics (BTAI) to $4 from $2 and keeps a Neutral...

1M ago

BTAI

Sell Rating on Bioxcel Therapeutics Amid Efficacy and Strategic Concerns

Analyst Alec Stranahan of Bank of America Securities maintained a Sell rating on Bioxcel Therapeutics, retaining the price...

1M ago

BTAI

BioXcel Therapeutics Reports Positive Phase 3 Trial Results

Bioxcel Therapeutics ( ($BTAI) ) has issued an update. On September 10, 2025, BioXcel Therapeutics announced positive results...

1M ago

BTAI

BioXcel reports results from SERENITY At-Home Pivotal Phase 3 safety trial

BioXcel Therapeutics (BTAI) announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial,...

1M ago

BTAI

BioXcel’s Phase 3 Trial Success for BXCL501

Bioxcel Therapeutics ( ($BTAI) ) has shared an update. On August 27, 2025, BioXcel Therapeutics announced that its...

2M ago

BTAI

BioXcel Therapeutics announces SERENITY Phase 3 trial met primary endpoint

BioXcel Therapeutics (BTAI) announced that the SERENITY At-Home Pivotal Phase 3 trial evaluating the safety of BXCL501, the...

2M ago

BTAI

BTAI FAQ

What was Bioxcel Therapeutics Inc’s price range in the past 12 months?

Bioxcel Therapeutics Inc lowest stock price was $1.17 and its highest was $13.28 in the past 12 months.

What is Bioxcel Therapeutics Inc’s market cap?

Bioxcel Therapeutics Inc’s market cap is $44.99M.

When is Bioxcel Therapeutics Inc’s upcoming earnings report date?

Bioxcel Therapeutics Inc’s upcoming earnings report date is Nov 13, 2025 which is in 22 days.

How were Bioxcel Therapeutics Inc’s earnings last quarter?

Bioxcel Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$2.45 earnings per share for the quarter, missing the consensus estimate of -$1.858 by -$0.592.

Is Bioxcel Therapeutics Inc overvalued?

According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bioxcel Therapeutics Inc pay dividends?

Bioxcel Therapeutics Inc does not currently pay dividends.

What is Bioxcel Therapeutics Inc’s EPS estimate?

Bioxcel Therapeutics Inc’s EPS estimate is -1.02.

How many shares outstanding does Bioxcel Therapeutics Inc have?

Bioxcel Therapeutics Inc has 19,646,801 shares outstanding.

What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?

Bioxcel Therapeutics Inc reported an EPS of -$2.45 in its last earnings report, missing expectations of -$1.858. Following the earnings report the stock price went up 6.25%.

Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?

Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at 0.

Bioxcel Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-60.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bioxcel Therapeutics Inc

Bioxcel Therapeutics, Inc. (BTAI) is a biopharmaceutical company that leverages artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The company is focused on discovering, developing, and commercializing innovative therapies through its proprietary AI platform designed to identify new therapeutic opportunities. Their core areas include treatments for acute agitation in patients with neuropsychiatric disorders and therapies targeting rare forms of cancer.

Bioxcel Therapeutics (BTAI) Earnings & Revenues

Historic Earnings Reports

BTAI Stock 12 Month Forecast

Average Price Target

$8.25

▲(260.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.57,3.756923076923077,4.943846153846154,6.13076923076923,7.317692307692308,8.504615384615384,9.691538461538462,10.87846153846154,12.065384615384616,13.252307692307692,14.43923076923077,15.626153846153848,16.813076923076924,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.57,3.006923076923077,3.443846153846154,3.8807692307692303,4.317692307692307,4.754615384615384,5.191538461538461,5.628461538461538,6.065384615384615,6.502307692307692,6.939230769230768,7.376153846153846,7.813076923076922,{"y":8.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.57,2.449230769230769,2.3284615384615384,2.2076923076923074,2.086923076923077,1.966153846153846,1.8453846153846154,1.7246153846153844,1.603846153846154,1.483076923076923,1.3623076923076922,1.2415384615384615,1.1207692307692307,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.84,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.29,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.98,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >